Shanghai Shen Lian Biomedical Corporation (SHA:688098)
China
· Delayed Price · Currency is CNY 8.93
+0.20 (2.29%)
Apr 29, 2026, 3:00 PM CST
SHA:688098 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 288.27 | 301.93 | 300.14 | 327.87 | 357.79 | Upgrade
|
| Other Revenue | - | 1.48 | 1.34 | 0.72 | 0.64 | Upgrade
|
| Revenue | 288.27 | 303.41 | 301.49 | 328.59 | 358.43 | Upgrade
|
| Revenue Growth (YoY) | -4.99% | 0.64% | -8.25% | -8.32% | 6.13% | Upgrade
|
| Cost of Revenue | 124.47 | 120.62 | 87.89 | 81.38 | 87.01 | Upgrade
|
| Gross Profit | 163.79 | 182.8 | 213.59 | 247.21 | 271.42 | Upgrade
|
| Selling, General & Admin | 134.29 | 155.91 | 134.72 | 128.69 | 120.97 | Upgrade
|
| Research & Development | 44.81 | 49.36 | 44.53 | 39.04 | 34.95 | Upgrade
|
| Other Operating Expenses | -1.08 | 2.76 | 3.54 | 3.43 | 3.57 | Upgrade
|
| Operating Expenses | 178.03 | 216.47 | 185.9 | 179.66 | 161.13 | Upgrade
|
| Operating Income | -14.23 | -33.67 | 27.7 | 67.56 | 110.29 | Upgrade
|
| Interest Expense | - | -0.02 | - | - | - | Upgrade
|
| Interest & Investment Income | - | 2.6 | 4.42 | 3.99 | 11.91 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0 | -0.02 | -0.05 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -11.74 | -0.08 | -0.08 | -0.01 | 0.07 | Upgrade
|
| EBT Excluding Unusual Items | -25.98 | -31.17 | 32.02 | 71.49 | 122.29 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.6 | 0.88 | 2.35 | 0.35 | 1.78 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.26 | -0.25 | -0.4 | 0.14 | -0.6 | Upgrade
|
| Asset Writedown | 0.01 | -28.17 | - | -0.24 | - | Upgrade
|
| Other Unusual Items | - | 1.91 | 2.3 | 2.82 | 2.52 | Upgrade
|
| Pretax Income | -26.31 | -56.79 | 36.27 | 74.55 | 125.98 | Upgrade
|
| Income Tax Expense | -1.34 | -8.05 | 6.41 | 13.58 | 21.52 | Upgrade
|
| Earnings From Continuing Operations | -24.97 | -48.75 | 29.85 | 60.97 | 104.46 | Upgrade
|
| Minority Interest in Earnings | 4.48 | 4.01 | 1.67 | 0.13 | 5.74 | Upgrade
|
| Net Income | -20.5 | -44.74 | 31.52 | 61.1 | 110.2 | Upgrade
|
| Net Income to Common | -20.5 | -44.74 | 31.52 | 61.1 | 110.2 | Upgrade
|
| Net Income Growth | - | - | -48.42% | -44.55% | -14.91% | Upgrade
|
| Shares Outstanding (Basic) | 410 | 407 | 394 | 407 | 408 | Upgrade
|
| Shares Outstanding (Diluted) | 410 | 407 | 394 | 407 | 408 | Upgrade
|
| Shares Change (YoY) | 0.78% | 3.23% | -3.28% | -0.20% | -2.31% | Upgrade
|
| EPS (Basic) | -0.05 | -0.11 | 0.08 | 0.15 | 0.27 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.11 | 0.08 | 0.15 | 0.27 | Upgrade
|
| EPS Growth | - | - | -46.67% | -44.44% | -12.90% | Upgrade
|
| Free Cash Flow | -12.16 | 4.45 | -126.11 | -84.04 | -98.04 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | 0.01 | -0.32 | -0.21 | -0.24 | Upgrade
|
| Dividend Per Share | - | - | 0.035 | 0.080 | - | Upgrade
|
| Dividend Growth | - | - | -56.25% | - | - | Upgrade
|
| Gross Margin | 56.82% | 60.25% | 70.85% | 75.23% | 75.72% | Upgrade
|
| Operating Margin | -4.94% | -11.10% | 9.19% | 20.56% | 30.77% | Upgrade
|
| Profit Margin | -7.11% | -14.75% | 10.45% | 18.59% | 30.75% | Upgrade
|
| Free Cash Flow Margin | -4.22% | 1.47% | -41.83% | -25.57% | -27.35% | Upgrade
|
| EBITDA | 60.79 | 34.15 | 90.85 | 124.49 | 153.91 | Upgrade
|
| EBITDA Margin | 21.09% | 11.25% | 30.13% | 37.89% | 42.94% | Upgrade
|
| D&A For EBITDA | 75.03 | 67.82 | 63.15 | 56.94 | 43.62 | Upgrade
|
| EBIT | -14.23 | -33.67 | 27.7 | 67.56 | 110.29 | Upgrade
|
| EBIT Margin | -4.94% | -11.10% | 9.19% | 20.56% | 30.77% | Upgrade
|
| Effective Tax Rate | - | - | 17.69% | 18.21% | 17.08% | Upgrade
|
| Revenue as Reported | - | 303.41 | 301.49 | - | 358.43 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.